[{"address1": "Life Science and Technology Park", "address2": "1951 NW 7th Avenue Suite 520", "city": "Miami", "state": "FL", "zip": "33136", "country": "United States", "phone": "305 909 0840", "website": "https://longeveron.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Dr. Joshua Michael Hare FACC, M.D.", "age": 60, "title": "Co-Founder, Chief Science Officer & Chairman", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 74000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mohamed Wa'el Ahmed Hashad", "age": 61, "title": "CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 781559, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa A. Locklear M.B.A.", "age": 61, "title": "Executive VP & CFO", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 248379, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul T. Lehr J.D.", "age": 55, "title": "International Executive Director, General Counsel & Secretary", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 554055, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dan  Gincel Ph.D.", "age": 52, "title": "Senior Vice President of Strategic Collaborations & Scientific Affairs", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nataliya  Agafanova M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elly  Ryu", "age": 41, "title": "VP & Corporate Controller", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.69, "open": 1.67, "dayLow": 1.65, "dayHigh": 1.8, "regularMarketPreviousClose": 1.69, "regularMarketOpen": 1.67, "regularMarketDayLow": 1.65, "regularMarketDayHigh": 1.8, "beta": 0.196, "forwardPE": -0.50442475, "volume": 203034, "regularMarketVolume": 203034, "averageVolume": 2141343, "averageVolume10days": 698750, "averageDailyVolume10Day": 698750, "bid": 1.69, "ask": 1.72, "bidSize": 300, "askSize": 300, "marketCap": 8204614, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 44.0, "priceToSalesTrailing12Months": 11.572093, "fiftyDayAverage": 3.5874, "twoHundredDayAverage": 15.83475, "currency": "USD", "enterpriseValue": 978014, "floatShares": 1804814, "sharesOutstanding": 3314020, "sharesShort": 91076, "sharesShortPriorMonth": 15400, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.019, "heldPercentInsiders": 0.18304001, "heldPercentInstitutions": 0.07546, "shortRatio": 0.02, "shortPercentOfFloat": 0.028299998, "impliedSharesOutstanding": 4798020, "bookValue": 2.685, "priceToBook": 0.6368715, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -22211000, "trailingEps": -10.2, "forwardEps": -3.39, "lastSplitFactor": "1:10", "lastSplitDate": 1711497600, "enterpriseToRevenue": 1.379, "enterpriseToEbitda": -0.049, "52WeekChange": -0.9431894, "SandP52WeekChange": 0.23099434, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "LGVN", "underlyingSymbol": "LGVN", "shortName": "Longeveron Inc.", "longName": "Longeveron Inc.", "firstTradeDateEpochUtc": 1613140200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0810e7c7-ed9c-3408-947e-be0c34d084bb", "messageBoardId": "finmb_410711455", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.71, "targetHighPrice": 15.15, "targetLowPrice": 12.0, "targetMeanPrice": 14.05, "targetMedianPrice": 15.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 5361000, "totalCashPerShare": 2.133, "ebitda": -20060000, "totalDebt": 2041000, "quickRatio": 1.407, "currentRatio": 1.504, "totalRevenue": 709000, "debtToEquity": 30.277, "revenuePerShare": 0.326, "returnOnAssets": -0.6649, "returnOnEquity": -1.57194, "freeCashflow": -11718750, "operatingCashflow": -19002000, "revenueGrowth": -0.479, "grossMargins": 0.31171, "operatingMargins": -85.98413, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]